Dual Inhibition of EGFR and mTOR Pathways in Small Cell Lung Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6605761
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comprehensive Analysis of EGFR Signaling Pathways in Japanese Patients With Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2009English

The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

CDK4/6 Inhibition Stabilizes Disease in Patients With P16-Null Non-Small Cell Lung Cancer and Is Synergistic With mTOR Inhibition

Oncotarget
Oncology
2018English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

Dual Inhibition of ULK1 and mTOR Enhances Tumor Cell Apoptosis

Cancer Discovery
Oncology
2015English

Dual Inhibition of EGFR With Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

Cancer Discovery
Oncology
2014English

Cryobiopsy Increases the EGFR Detection Rate in Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

A Novel Dual PI3Kα/mTOR Inhibitor PI-103 With High Antitumor Activity in Non-Small Cell Lung Cancer Cells

International Journal of Molecular Medicine
MedicineGenetics
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy